Cargando…

ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients

BACKGROUND: Receptor tyrosine-protein kinase erbB-2 (ERBB2) expression is a critical factor for the prognosis of various cancers. ERBB2 enrichment indicates a poor prognosis in some cancer types but could be a favorable prognostic factor in others. METHODS: We analyzed DNA methylation, mRNA, protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hongting, Jiang, Yongxu, Jin, Huanhuan, Wang, Cunqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511046/
https://www.ncbi.nlm.nih.gov/pubmed/36172165
http://dx.doi.org/10.3389/fonc.2022.1012138
_version_ 1784797576016429056
author Wang, Hongting
Jiang, Yongxu
Jin, Huanhuan
Wang, Cunqin
author_facet Wang, Hongting
Jiang, Yongxu
Jin, Huanhuan
Wang, Cunqin
author_sort Wang, Hongting
collection PubMed
description BACKGROUND: Receptor tyrosine-protein kinase erbB-2 (ERBB2) expression is a critical factor for the prognosis of various cancers. ERBB2 enrichment indicates a poor prognosis in some cancer types but could be a favorable prognostic factor in others. METHODS: We analyzed DNA methylation, mRNA, protein, immune cell infiltration, and related signaling pathways using TIMER2.0, GEPIA2, STRING, and UALCAN portal datasets in tumor tissues of diverse cancer types and their matched normal tissues. RESULTS: ERBB2 promoter demethylation increases transcript protein amplification and promotes a poor prognosis for cancer patients. ERBB2 gain-of-function procures immune cell infiltration for tumor growth and drives away T regulatory cells, which suppress or downregulate induction and proliferation of effector T cells. The downstream signaling pathways, such as tumor proliferation, ECM-related genes, and degradation of ECM, are involved in ERBB2 gene demethylation and immune activation in cancer progression. CONCLUSION: ERBB2 gene demethylation leads to a poor prognosis in cancer patients, which is strongly influenced by the composition and abundance of tumor immune cell infiltration. ERBB2 demethylation could be used in clinical practice to identify immune profiles and direct therapeutic strategies.
format Online
Article
Text
id pubmed-9511046
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95110462022-09-27 ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients Wang, Hongting Jiang, Yongxu Jin, Huanhuan Wang, Cunqin Front Oncol Oncology BACKGROUND: Receptor tyrosine-protein kinase erbB-2 (ERBB2) expression is a critical factor for the prognosis of various cancers. ERBB2 enrichment indicates a poor prognosis in some cancer types but could be a favorable prognostic factor in others. METHODS: We analyzed DNA methylation, mRNA, protein, immune cell infiltration, and related signaling pathways using TIMER2.0, GEPIA2, STRING, and UALCAN portal datasets in tumor tissues of diverse cancer types and their matched normal tissues. RESULTS: ERBB2 promoter demethylation increases transcript protein amplification and promotes a poor prognosis for cancer patients. ERBB2 gain-of-function procures immune cell infiltration for tumor growth and drives away T regulatory cells, which suppress or downregulate induction and proliferation of effector T cells. The downstream signaling pathways, such as tumor proliferation, ECM-related genes, and degradation of ECM, are involved in ERBB2 gene demethylation and immune activation in cancer progression. CONCLUSION: ERBB2 gene demethylation leads to a poor prognosis in cancer patients, which is strongly influenced by the composition and abundance of tumor immune cell infiltration. ERBB2 demethylation could be used in clinical practice to identify immune profiles and direct therapeutic strategies. Frontiers Media S.A. 2022-09-12 /pmc/articles/PMC9511046/ /pubmed/36172165 http://dx.doi.org/10.3389/fonc.2022.1012138 Text en Copyright © 2022 Wang, Jiang, Jin and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Hongting
Jiang, Yongxu
Jin, Huanhuan
Wang, Cunqin
ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients
title ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients
title_full ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients
title_fullStr ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients
title_full_unstemmed ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients
title_short ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients
title_sort erbb2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511046/
https://www.ncbi.nlm.nih.gov/pubmed/36172165
http://dx.doi.org/10.3389/fonc.2022.1012138
work_keys_str_mv AT wanghongting erbb2promoterdemethylationandimmunecellinfiltrationpromoteapoorprognosisforcancerpatients
AT jiangyongxu erbb2promoterdemethylationandimmunecellinfiltrationpromoteapoorprognosisforcancerpatients
AT jinhuanhuan erbb2promoterdemethylationandimmunecellinfiltrationpromoteapoorprognosisforcancerpatients
AT wangcunqin erbb2promoterdemethylationandimmunecellinfiltrationpromoteapoorprognosisforcancerpatients